NasdaqGS:ANAB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has AnaptysBio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ANAB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.0%

ANAB

0.5%

US Biotechs

3.0%

US Market


1 Year Return

-74.1%

ANAB

27.3%

US Biotechs

9.9%

US Market

Return vs Industry: ANAB underperformed the US Biotechs industry which returned 27.3% over the past year.

Return vs Market: ANAB underperformed the US Market which returned 9.9% over the past year.


Shareholder returns

ANABIndustryMarket
7 Day-4.0%0.5%3.0%
30 Day24.9%9.2%8.2%
90 Day10.2%12.8%0.4%
1 Year-74.1%-74.1%28.6%27.3%12.4%9.9%
3 Year-14.9%-14.9%34.7%30.2%31.0%22.3%
5 Yearn/a-1.9%-7.8%58.1%40.3%

Price Volatility Vs. Market

How volatile is AnaptysBio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AnaptysBio undervalued compared to its fair value and its price relative to the market?

1.3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ANAB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ANAB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ANAB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ANAB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANAB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ANAB is good value based on its PB Ratio (1.3x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is AnaptysBio forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-11.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANAB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANAB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANAB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANAB's revenue (23.7% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: ANAB's revenue (23.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ANAB is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has AnaptysBio performed over the past 5 years?

-59.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ANAB is currently unprofitable.

Growing Profit Margin: ANAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ANAB is unprofitable, and losses have increased over the past 5 years at a rate of -59.6% per year.

Accelerating Growth: Unable to compare ANAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: ANAB has a negative Return on Equity (-20.85%), as it is currently unprofitable.


Next Steps

Financial Health

How is AnaptysBio's financial position?


Financial Position Analysis

Short Term Liabilities: ANAB's short term assets ($371.1M) exceed its short term liabilities ($23.3M).

Long Term Liabilities: ANAB's short term assets ($371.1M) exceed its long term liabilities ($419.0K).


Debt to Equity History and Analysis

Debt Level: ANAB is debt free.

Reducing Debt: ANAB has no debt compared to 5 years ago when its debt to equity ratio was 69.8%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ANAB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ANAB has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 53.1% each year


Next Steps

Dividend

What is AnaptysBio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANAB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ANAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Hamza Suria (43yo)

8.92yrs

Tenure

US$7,875,186

Compensation

Mr. Hamza Suria, M.Sc., M.B.A. has been the Chief Executive Officer and President of AnaptysBio, Inc., since July 2011. Mr. Suria served as an Acting Chief Executive Officer and Chief Business Officer of A ...


CEO Compensation Analysis

Compensation vs Market: Hamza's total compensation ($USD7.88M) is above average for companies of similar size in the US market ($USD2.21M).

Compensation vs Earnings: Hamza's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Hamza Suria
President8.92yrsUS$7.88m0.17% $908.9k
Eric Loumeau
Interim CFO & General Counsel0.83yrUS$3.54mno data
Beth Mueller
Senior Vice President of Human Resources0.67yrno datano data
Margaret Marino
Senior Vice President of Project Management0.42yrno datano data
David McKeon
VP & Controller1.33yrsno datano data

0.8yrs

Average Tenure

47yo

Average Age

Experienced Management: ANAB's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Hamza Suria
President8.92yrsUS$7.88m0.17% $908.9k
Hollings Renton
Lead Independent Directorno dataUS$318.99kno data
John Schmid
Independent Director5yrsUS$310.96kno data
Dennis Fenton
Independent Director2.25yrsUS$318.99kno data
James Topper
Independent Chairmanno dataUS$320.24k0.12% $607.8k
J. Ware
Independent Director2.83yrsUS$317.74k0.013% $68.7k
Laura Hamill
Independent Director0.75yrUS$204.25kno data

2.8yrs

Average Tenure

57yo

Average Age

Experienced Board: ANAB's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AnaptysBio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AnaptysBio, Inc.
  • Ticker: ANAB
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$520.447m
  • Shares outstanding: 27.28m
  • Website: https://www.anaptysbio.com

Number of Employees


Location

  • AnaptysBio, Inc.
  • 10421 Pacific Center Court
  • Suite 200
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ANABNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 2017
AN6DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2017
0HFQLSE (London Stock Exchange)YesCommon StockGBUSDJan 2017
ANAB *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 2017

Biography

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company’s products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; and collaboration with Celgene Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/01 05:34
End of Day Share Price2020/05/29 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.